HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Mankind Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Mankind Pharma Intelligence Report

Generated from 9 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 74%

Evidence

54 items

Sources

10

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Mankind Pharma maintains an active intelligence profile across Cardiovascular, Statin, Anticholinergic, Anesthesia, Neuromuscular Blockade. 9 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 74% across 2 tracked sources. Highest-priority development: FDA AP — RIVAROXABAN (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mankind Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — RIVAROXABAN (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 468 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — RIVAROXABAN (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Brimonidine Tartrate Application ANDA220398 by Mankind Pharma

    Ophthalmology · Glaucoma

  • FDA Approval Application for Rivaroxaban by Mankind Pharma

    Cardiovascular · Anticoagulant

  • Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status

    Cardiovascular · Statin

  • FDA grants AP status for Atropine Sulfate ANDA218148 by Mankind Pharma

    Cardiovascular · Anticholinergic

  • FDA Accepts Sugammadex Sodium Application from Mankind Pharma

    Anesthesia · Neuromuscular Blockade

  • FDA Submission for Sitagliptin and Metformin Hydrochloride by Mankind Pharma

    Diabetes · DPP-4 Inhibitor and Biguanide

  • FDA Grants Approval for Brimonidine Tartrate ANDA220398 by Mankind Pharma

    Ophthalmology · Glaucoma

  • FDA Grants AP Status for Atropine Sulfate ANDA218148 by Mankind Pharma

    Cardiovascular · Anticholinergic

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.